|2.2 0.04 (1.85%)||12-01 16:00|
|Targets||6-month :||12.32||1-year :||18.46|
|Resists||First :||10.55||Second :||15.8|
|Supports||First :||2.05||Second :||1.71|
|MAs||MA(5) :||2.25||MA(20) :||3.63|
|MA(100) :||24.73||MA(250) :||31.46|
|MACD||MACD :||-3.7||Signal :||-4.4|
|%K %D||K(14,3) :||10.2||D(3) :||6.2|
|52-week||High :||47.25||Low :||2.05|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VTYX ] has closed above bottom band by 7.8%. Bollinger Bands are 96.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||2.24 - 2.25||2.25 - 2.26|
|Low:||2.03 - 2.04||2.04 - 2.06|
|Close:||2.17 - 2.2||2.2 - 2.23|
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||59 (M)|
|Shares Float||48 (M)|
|Held by Insiders||3.7 (%)|
|Held by Institutions||102.4 (%)|
|Shares Short||7,420 (K)|
|Shares Short P.Month||9,340 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||4.8|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-33.1 %|
|Return on Equity (ttm)||-54.4 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-162 (M)|
|Levered Free Cash Flow||-106 (M)|
|Price to Book value||0.45|
|Price to Sales||0|
|Price to Cash Flow||-0.81|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|